Skip to main content

Table 2 Baseline clinical characteristics of the study patients

From: Deciphering the gene expression profile of peroxisome proliferator-activated receptor signaling pathway in the left atria of patients with mitral regurgitation

  MR (n = 15) AVD (n = 7) NC (n = 3) P value
Age (years) 57 ± 9 60 ± 11   0.458
Male (%) 6 (40.0 %) 6 (85.7 %)   0.059
Smoking (%) 2 (13.3 %) 1 (14.3 %)   0.705
Body mass index (kg/m2) 23.5 ± 2.3 24.2 ± 3.3   0.259
Hypertension (%) 7 (46.7 %) 4 (57.1 %)   0.500
Diabetes mellitus (%) 2 (13.3 %) 1 (14.3 %)   0.705
Hyperlipidemia (%) 6 (40.0 %) 2 (28.6 %)   0.490
NYHA     0.506
 Functional class I (%) 2 (13.3 %) 1 (14.3 %)   
 Functional class II (%) 7 (46.7 %) 3 (42.9 %)   
 Functional class III (%) 6 (40.0 %) 2 (28.6 %)   
 Functional class IV (%) 0 (0.0 %) 1 (14.3 %)   
Aortic valve disease (%) 0 (0.0 %) 7 (100.0 %)   <0.001
Tricuspid regurgitation (%) 7 (46.7 %) 1 (14.3 %)   0.161
β-blockers (%) 5 (33.3 %) 0 (0.0 %)   0.114
Calcium channel blockers (%) 6 (40.0 %) 3 (42.9 %)   0.628
Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers (%) 12 (80.0 %) 3 (42.9 %)   0.107
Creatinine (mg/dl) 0.9 ± 0.7 1.0 ± 0.3   0.139
White blood cell count (103/uL) 6.3 ± 1.5 5.6 ± 1.8   0.289
Left atrial diameter (mm) 45.5 ± 6.0 38.9 ± 5.8   0.028
Left atrial maximal volume (mL) 87.3 ± 42.6 42.5 ± 25.6   0.032
Left atrial ejection fraction (%) 49.7 ± 11.9 45.6 ± 18.7   0.654
Left ventricular end-diastolic diameter (mm) 58.2 ± 7.3 59.9 ± 12.7   0.397
Left ventricular ejection fraction (%) 67.3 ± 11.5 61.6 ± 12.9   0.340
  1. Data are presented as mean ± SD or number (percentage)
  2. AVD aortic valve disease, MR mitral regurgitation, NC purchased normal controls, NYHA New York Heart Association, P value MR vs. AVD